Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

M.D. Anderson Cancer Center clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3096
Shown on this page
12
Current sort
Recently updated
Sponsor scope
M.D. Anderson Cancer Center
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within M.D. Anderson Cancer Center. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 901–912 of 3,096 matching trials for sponsor M.D. Anderson Cancer Center.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic

NCT04482647
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Media Intervention, Meditation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

NCT07316010
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
Leukapheresis, Lymphodepleting Chemotherapy
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Not yet recruiting Not applicable Interventional

Oncologic Timely Palliative Care And Remote Monitoring With Electronic Assessments And Telehealth (ON-TARGET)

NCT07674797
View directory record Official record
Conditions
Oncologic, Palliative Care, Remote Monitoring, Electronic Assessments, Telehealth
Interventions
Questionnaire and Physical Exam
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

NCT07674810
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Zanubrutinib, Obinutuzumab, Sonrotoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

NCT07318324
View directory record Official record
Conditions
Phase IB, Avutometinib, RAS Pathway, Endometrial
Interventions
Avutometinib, defactinib, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Lenalidomide, Valemetostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

NCT01209871
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma
Interventions
Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198
View directory record Official record
Conditions
Metastatic Colorectal Cancer, KRAS G12C Mutations
Interventions
Cetuximab, Cemiplimab, Adagrasib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital

NCT07591701
View directory record Official record
Conditions
Prostate Cancer
Interventions
Video
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Early Phase 1 Interventional

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

NCT06744816
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
Qutenza Patch
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Data Collection Protocol for Patients With Von Hippel Lindau Disease

NCT05955014
View directory record Official record
Conditions
Von Hippel Lindau Disease
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

NCT04151082
View directory record Official record
Conditions
Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
Interventions
Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:37 PM EDT

About this M.D. Anderson Cancer Center sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where M.D. Anderson Cancer Center is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within M.D. Anderson Cancer Center trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at MD Anderson Cancer Center in Houston, TX, or open the full search for M.D. Anderson Cancer Center.